10-12 September 2018 //  Lancaster Royal Hotel, London


Cedrik Britten

Dr Cedrik Britten

Head, Cellular Therapy Immuno-Oncology, GlaxoSmithKline

Dr. Cedrik Britten is the Head of Cell Therapy within GSK’s Immuno-Oncology and Combinations Unit. At GSK he heads a group developing innovative immunotherapies for treatment of cancer patients with high unmet medical need that are based on immune-receptor engineered immune-cells. Dr. Britten is a physician and immunologist who has worked in Tumour–Immunology since 1998. Prior to joining GSK he was Vice President R&D at BioNTech RNA Pharmaceuticals developing highly personalized immunotherapies. He has also been initiating and leading field-serving working groups within the non-for profit Association for Cancer Immunotherapy since 2003 with focus on novel biomarkers, regularity framework for novel personalized medicine approaches and commercialisation of technologies.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad